The global veterinary ophthalmology equipment market is expected to grow from USD 0.57 billion in 2026 to USD 0.83 billion by 2031, at a 7.7% CAGR. Growth is driven by rising pet ownership, increased prevalence of animal eye diseases, and adoption of advanced diagnostic and surgical technologies. Treatment applications and surgical equipment segments are leading growth, with Asia Pacific emerging as the fastest-growing region.

Bausch + Lomb (BLCO) announced that its SeeLyra femtosecond laser received European CE Mark approval, expanding its surgical technology portfolio. The platform uses live swept-source OCT for real-time visualization and precise surgical control in cataract, LASIK, and corneal procedures. A limited European launch is planned with broader availability expected in 2027. The global ophthalmic femtosecond lasers market is projected to grow at 7.5% CAGR through 2033.

Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.

The global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, Alcon, Bausch + Lomb, and HOYA Corporation, with North America currently leading the market while Asia-Pacific shows rapid growth potential.

Bausch + Lomb director Alfonso Eduardo purchased 4,300 shares for approximately $77,000 on March 2, 2026, at $17.90 per share. The company matched his purchase with 4,300 restricted stock units granted at no cost, vesting over three years. As a new director (joined January 1, 2026), Eduardo is working toward a mandatory $400,000 equity ownership requirement within five years, with this transaction bringing him to roughly $248,000 of that threshold.

The Portnoy Law Firm has initiated a securities fraud investigation into Bausch + Lomb Corporation following significant stock price declines. The company's stock fell 9.8% on March 28, 2025, after disclosing increased reports of toxic anterior segment syndrome (TASS) related to enVista intraocular lenses, prompting a voluntary recall. A second decline of 15.7% occurred on April 30, 2025, following Q1 2025 results estimating $55 million in revenue and $65 million in adjusted EBITDA headwinds from the recall.

Bausch + Lomb reported $5.1 billion in annual revenue with 6% year-over-year growth, driven by contact lenses, consumer eye health products, and new pharmaceutical launches like MIEBO. Caspian Capital increased its stake by 1.35 million shares to $34.14 million, making it the firm's top holding at 22.6% of AUM. Despite underperforming the S&P 500 over the past year, the stock has stabilized recently and analysts view the investor's conviction as a positive signal.

The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.

Nicox announced positive Phase 3 data for NCX 470, a nitric oxide-donating bimatoprost eye drop, presented at the American Glaucoma Society 2026 congress. The drug demonstrated intraocular pressure (IOP) reduction up to 10 mmHg, meeting efficacy requirements for U.S. and China regulatory approvals. NCX 470 showed superior IOP reduction compared to latanoprost at three of six measurement points and demonstrated a favorable safety profile with low treatment discontinuation rates.

Nicox announced that Phase 3 study results for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma treatment, will be presented at the American Glaucoma Society annual congress in February 2026, including two oral presentations. The company is preparing regulatory submissions for NCX 470 in the United States and China with licensed partners Kowa and Ocumension Therapeutics.

Nicox SA announced its participation in major ophthalmology, finance, and industry conferences during the first half of 2026, including the American Glaucoma Society Annual Congress in February. The company will present key data from its Denali and Whistler studies on NCX 470, its lead clinical program for treating glaucoma and ocular hypertension.

Nicox SA announced its participation in multiple key ophthalmology and financial conferences in the first half of 2026, including the American Glaucoma Society Annual Meeting in February where it will present multiple data presentations on NCX 470 from the Denali and Whistler studies. The company will also attend investor conferences and industry events across Europe and the U.S., with management available for one-on-one meetings.